Fabien Moinard-Butot - JoVE Visualize

Showing results (21-30 of 24) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 24 results.

Clinical Genitourinary Cancer|February 7, 2026

Real-World Outcomes of First-Line Immune-Based Combination Therapies in Bone-Metastatic Clear Cell Renal Cell CarcinomaAlia Harba, Fabien Moinard-Butot, Edouard Auclin, et al.

American Journal of Physiology. Cell Physiology|April 16, 2026

NF-κB signaling drives rapid skeletal muscle atrophy in patients with breast cancer: The cost of fighting cancer with chemotherapyJoris Mallard, Léa Debrut, Elyse Hucteau, et al.

Cancer Immunology, Immunotherapy : CII|May 24, 2026

Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad studyKarim Amrane, Luca Campedel, Fabien Moinard-Butot, et al.

Breast (Edinburgh, Scotland)|March 17, 2022

Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohortFabien Moinard-Butot, Caroline Saint-Martin, Carole Pflumio, et al.

Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 24 results.

Clinical Genitourinary Cancer|February 7, 2026

Real-World Outcomes of First-Line Immune-Based Combination Therapies in Bone-Metastatic Clear Cell Renal Cell CarcinomaAlia Harba, Fabien Moinard-Butot, Edouard Auclin, et al.

American Journal of Physiology. Cell Physiology|April 16, 2026

NF-κB signaling drives rapid skeletal muscle atrophy in patients with breast cancer: The cost of fighting cancer with chemotherapyJoris Mallard, Léa Debrut, Elyse Hucteau, et al.

Cancer Immunology, Immunotherapy : CII|May 24, 2026

Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad studyKarim Amrane, Luca Campedel, Fabien Moinard-Butot, et al.

Breast (Edinburgh, Scotland)|March 17, 2022

Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohortFabien Moinard-Butot, Caroline Saint-Martin, Carole Pflumio, et al.

Pageof 3